What question did this study set out to answer?

To assess the PMAPscore-based risk model's effectiveness in predicting survival and immunotherapy responses in advanced gastric cancer.

March 19, 2026Advances in Clinical and Experimental Medicine0 citationsOpen Access

Pathway Mutation Accumulate Perturbation Score: A prognostic and predictive biomarker for immunotherapy in advanced gastric cancer

ZZZiyan ZhangBaotou Medical College GYGuihua YangBerry Oncology (China)YXYuming XingBeijing University of Posts and Telecommunications

Key Points

To assess the PMAPscore-based risk model's effectiveness in predicting survival and immunotherapy responses in advanced gastric cancer.
Developed a risk model using PMAPscore
Analyzed survival rates in advanced gastric cancer patients
Evaluated immunotherapy response correlated with PMAPscore
PMAPscore effectively predicts survival outcomes
Improved identification of patients likely to benefit from immunotherapy
Supports clinical use for tailoring treatment strategies

Abstract

The PMAPscore-based risk model is a robust tool for predicting survival and immunotherapy responses in patients with advanced GC, supporting its clinical application for treatment stratification.

KI fragen

Bookmark

View Full Paper